Kymera Therapeutics, Inc.
KYMR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $4,941,196 | $3,510,812 | $2,193,611 | $3,217,894 |
| - Cash | $112,949 | $335,816 | $89,966 | $120,256 |
| + Debt | $83,997 | $85,714 | $86,330 | $87,761 |
| Enterprise Value | $4,912,244 | $3,260,710 | $2,189,975 | $3,185,399 |
| Revenue | $2,764 | $11,476 | $22,100 | $7,394 |
| % Growth | -75.9% | -48.1% | 198.9% | – |
| Gross Profit | -$71,330 | $9,392 | $22,100 | $7,394 |
| % Margin | -2,580.7% | 81.8% | 100% | 100% |
| EBITDA | -$79,326 | -$74,422 | -$63,461 | -$68,706 |
| % Margin | -2,870% | -648.5% | -287.2% | -929.2% |
| Net Income | -$82,175 | -$76,614 | -$65,581 | -$70,752 |
| % Margin | -2,973% | -667.6% | -296.7% | -956.9% |
| EPS Diluted | -0.94 | -0.95 | -0.82 | -0.88 |
| % Growth | 1.1% | -15.9% | 6.8% | – |
| Operating Cash Flow | -$27,110 | -$59,884 | -$79,150 | -$61,784 |
| Capital Expenditures | -$181 | -$695 | -$467 | -$936 |
| Free Cash Flow | -$27,291 | -$60,579 | -$79,617 | -$62,720 |